Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations
International Journal of Clinical Practice, Volume 61, No. 5, Year 2007
Notification
URL copied to clipboard!
Description
This randomised, double-blind, 6-month study compared budesonide/formoterol for maintenance and relief with salmeterol/fluticasone and a fixed maintenance dose of budesonide/formoterol, both with terbutaline for relief. Following a 2-week run-in, 3335 symptomatic adults and adolescents (mean FEV1 73% predicted, mean inhaled corticosteroid dose 745 μg/day) received budesonide/formoterol 160/4.5 μg one inhalation bid plus additional inhalations as needed, salmeterol/fluticasone 25/125 μg two inhalations bid plus as-needed terbutaline or budesonide/formoterol 320/9 μg one inhalation bid plus as-needed terbutaline. Budesonide/formoterol for maintenance and relief prolonged the time to first severe exacerbation requiring hospitalisation, emergency room treatment or oral steroids (primary variable) vs. fixed-dose salmeterol/fluticasone and budesonide/formoterol (p = 0.0034 and p = 0.023 respectively; log-rank test). Exacerbation rates were 19, 16 and 12 events/100 patients/6 months for salmeterol/fluticasone, fixed-dose budesonide/formoterol and budesonide/formoterol for maintenance and relief, respectively, [rate reduction vs. fixed-dose salmeterol/fluticasone (0.61; 95% CI 0.49-0.76, p < 0.001) and vs. fixed-dose budesonide/formoterol (0.72; 95% CI 0.57-0.90, p = 0.0048)]. Budesonide/formoterol maintenance and relief patients used less inhaled corticosteroid vs. salmeterol/fluticasone and fixed-dose budesonide/formoterol patients. All treatments provided similar marked improvements in lung function, asthma control days and asthma-related quality of life. Budesonide/formoterol for maintenance and relief reduces asthma exacerbations and maintains similar daily asthma control at a lower overall drug load compared with fixed-dose salmeterol/fluticasone and budesonide/formoterol. © 2007 The Authors.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC1920547/bin/ijcp0061-0725_p1.ppt
Authors & Co-Authors
Kuna, P.
Poland, Lodz
Uniwersytecki Szpital Kliniczny nr 1 Im. Norberta Barlickiego w Lodz
Peters, Matthew John
Australia, Sydney
Concord Repatriation General Hospital
Manjra, Ahmed Ismail
South Africa, Westville
Westville Hospital
Jorup, Carin
Sweden, Sodertalje
Astrazeneca Sweden
Naya, Ian P.
Sweden, Sodertalje
Astrazeneca Sweden
Martínez-Jiménez, Norma E.
Mexico, Mexico
Instituto de Seguridad y Servicios Sociales de Los Trabajadores Del Estado - Issste
Buhl, Roland Otto
Germany, Mainz
Universitätsmedizin Mainz
Statistics
Citations: 275
Authors: 7
Affiliations: 6
Identifiers
Doi:
10.1111/j.1742-1241.2007.01338.x
ISSN:
13685031
e-ISSN:
17421241
Research Areas
Disability
Health System And Policy